Health utilities in mild cognitive impairment and dementia: a population study in Sweden

Ekman, Mattias; Berg, Jenny; Wimo, Anders; Jönsson, Linus; McBurney, Christopher R.

doi:10.1002/gps.1725

Cited by 23 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Animal Medical Center site represents a large referral center within a busy urban environment (ie, New York City); however, other study sites, such as Angell Animal Medical Center and University of Pennsylvania, are in similar urban environments (Boston and Philadelphia, respectively), yet clients of these institutions failed to demonstrate the same preference. It is tempting to speculate that sociodemographic factors such as ethnicity, economic status, religion, and other variables, which play a role in personal end of life preferences, 7–9 extend to choices made for one's pets. On average, residents of the Manhattan borough of New York City have higher median incomes and smaller households and family sizes compared with the rest of the United States, 10 and perhaps the financial ability to provide long‐term care or the presence of fewer human companions influence a cat owner's desire to prolong life.…”

Section: Discussionmentioning

confidence: 99%

Perceptions of Quality of Life and Priorities of Owners of Cats with Heart Disease

Reynolds

Oyama

Rush

et al. 2010

Journal of Veterinary Internal Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Perceptions of Quality of Life and Priorities of Owners of Cats with Heart Disease

Reynolds

Oyama

Rush

et al. 2010

Journal of Veterinary Internal Medicine

View full text Add to dashboard Cite

show abstract

“…CDR scores have been found to correlate well with other measures and to predict institutionalization and death [11]. CDR has also been correlated with patient quality of life and costs [12]. The lowest scores on the CDR (0.5 and 1) were combined and classified as mild as has been done previously [13].…”

Section: Methodsmentioning

confidence: 99%

Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS

Spackman¹,

Kadiyala²,

Neumann³

et al. 2012

CAR

View full text Add to dashboard Cite

Objectives Estimate the probabilities, for Alzheimer's disease (AD) patients, of transitioning between stages of disease severity (mild, moderate, severe, dead) and care settings (community, institutional). Methods Data were compiled by the National Alzheimer Coordinating Center. The main analyses were limited to 3,852 patients who were >50 years old, diagnosed with possible/probable AD and had at least two center visits. A multinomial logistic model accounting for patient and center level correlation was used to calculate transition probabilities between stages of the Clinical Dementia Rating (CDR). Separately we calculated the probabilities of being institutionalized based on CDR stage. Both analyses controlled for baseline age, time between visits, sex, marital status, whether white, whether Hispanic and number of years of education. Results The annual probabilities of dying for patients in mild, moderate and severe health states were 5.5%, 21.5% and 48.0%, respectively, while the annual probabilities for institutionalization were 1.2%, 3.4% and 6.6%, respectively. The majority of mild and moderate patients remain in the same health state after one year, 77.4% and 50.1% respectively. Progressing patients are most likely to transition one stage, but 1.3% of mild patients become severe in one year. Some patients revert to lower severity stages, 7% from moderate to mild. Conclusions Transition probabilities to higher CDR stages and to institutionalization are lower than those published previously, but the probability of death is higher. These results are useful for understanding AD progression and can be used in simulation models to evaluate costs and compare new treatments or policies.

show abstract

“…Health utilities for patients with non-AD were estimated by adjusting 0.006 lower compared to their AD counterparts [39]. A utility weight of 0.82 was used for patients with predementia [40]. Caregiver utilities were predicted with an equation (Table 2) from a report by Getsios and colleagues [25].…”

Section: Methodsmentioning

confidence: 99%

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps

Guo¹,

Getsios²,

Hernández³

et al. 2012

International Journal of Alzheimer's Disease

View full text Add to dashboard Cite

The growing understanding of the use of biomarkers in Alzheimer's disease (AD) may enable physicians to make more accurate and timely diagnoses. Florbetaben, a beta-amyloid tracer used with positron emission tomography (PET), is one of these diagnostic biomarkers. This analysis was undertaken to explore the potential value of florbetaben PET in the diagnosis of AD among patients with suspected dementia and to identify key data that are needed to further substantiate its value. A discrete event simulation was developed to conduct exploratory analyses from both US payer and societal perspectives. The model simulates the lifetime course of disease progression for individuals, evaluating the impact of their patient management from initial diagnostic work-up to final diagnosis. Model inputs were obtained from specific analyses of a large longitudinal dataset from the New England Veterans Healthcare System and supplemented with data from public data sources and assumptions. The analyses indicate that florbetaben PET has the potential to improve patient outcomes and reduce costs under certain scenarios. Key data on the use of florbetaben PET, such as its influence on time to confirmation of final diagnosis, treatment uptake, and treatment persistency, are unavailable and would be required to confirm its value.

show abstract

Health utilities in mild cognitive impairment and dementia: a population study in Sweden

Cited by 23 publications

References 16 publications

Perceptions of Quality of Life and Priorities of Owners of Cats with Heart Disease

Perceptions of Quality of Life and Priorities of Owners of Cats with Heart Disease

Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps

Contact Info

Product

Resources

About